TriSalus Life Sciences announced the successful completion of its previously disclosed exchange offer and consent solicitation for its Series A Convertible Preferred Stock, which expired on July 23, 2025. The company reported that approximately 98.82% of the outstanding shares of Preferred Stock were tendered in the offer.
All validly tendered shares will be accepted, with settlement expected by August 1, 2025. Due to the high participation rate, TriSalus received approval to amend the terms of the Preferred Stock, allowing for the automatic conversion of all remaining outstanding preferred shares into common stock at an 11.3% lower exchange rate.
The SEC declared the company’s Registration Statement on Form S-4, registering the shares issuable in the offer and pursuant to the amendment, effective on July 22, 2025. This successful initiative significantly streamlines TriSalus's capital structure, reducing complexity and potential future dilution for common stockholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.